Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 6/20 | 1.00 |
| ▸ | DAO | P14920 | 1/20 | 0.67 |
| ▸ | CCR2 | P41597 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HNF4A | P41235 | 2/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814 | 1.00 | LDHA (1.00) | LDHADAOCCR2MCL1MAOA | |
| SCHEMBL7108 | 0.90 | LDHA (0.82) | LDHADAOCCR2MCL1MAOA | |
| SCHEMBL13306 | 0.89 | LDHA (0.79) | LDHADAOCCR2 | |
| SCHEMBL8712 | 0.88 | LDHA (0.78) | LDHADAOCCR2ALDH1A1 | |
| SCHEMBL7582 | 0.87 | LDHA (0.77) | LDHADAOCCR2MCL1ALDH1A1 | |
| SCHEMBL7835 | 0.87 | LDHA (0.77) | LDHADAOCCR2MCL1 | |
| SCHEMBL13308 | 0.87 | LDHA (1.00) | LDHADAOCCR2MCL1MAOA | |
| SCHEMBL7269 | 0.83 | LDHA (0.71) | LDHADAOCCR2MAOAMAOB | |
| SCHEMBL7574 | 0.83 | LDHA (0.71) | LDHADAOCCR2 | |
| SCHEMBL14118807 | 0.82 | LDHA (0.69) | LDHADAOCCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | claimed |
| US-9750761-B2 | LDH inhibitors as treatment for fibrosis and fibrotic-related disorders | UNIVERSITY OF ROCHESTER (US) | 2017-09-05 | — | — | US | disclosed |
| US-20150335674-A1 | LDH INHIBITORS AS TREATMENT FOR FIBROSIS AND FIBROTIC-RELATED DISORDERS | UNIVERSITY OF ROCHESTER (US) | 2015-11-26 | — | — | US | disclosed |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | disclosed |
| EP-2499114-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Universita Di Pisa (IT) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011054525-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITA' DI PISA (IT) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LDHA, LDHB, DLD | LDHA 1/4885DAO 565/4885CCR2 4452/4885 |
| US-20150335674-A1 | LDH INHIBITORS AS TREATMENT FOR FIBROSIS AND FIBROTIC-RELATED DISORDERS | LDHA, LDHB, ALDH1A2 | LDHA 1/4885DAO 532/4885CCR2 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.